Abstract
Hepatocellular carcinoma (HCC) is an important health problem around the world. It represents >85% of primary liver cancers worldwide. Chronic hepatitis C (CHC) infection is one of the major etiologic factors that cause HCC by producing an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. In general, HCC develops only after many years of hepatitis C virus (HCV) infection. The increased risk is limited to a great extent to patients with cirrhosis or advanced fibrosis. Given the current prevalence of HCV infection in Middle Eastern countries, the incidence and mortality rates of HCC are likely to increment throughout the following 10 years. Therefore, this chapter reviews the epidemiology, pathogenesis, and risk factors of HCV and HCV-related HCC in the Middle East (ME). Besides, the preventive and treatment strategies of HCV-related HCC are discussed individually. The comprehensive understanding of opportunities and limitations for successfully implementing the World Health Organization (WHO) HCV elimination targets by 2030 in the ME will help to develop strategies and plans tailored to each country's needs in this region.
| Original language | English |
|---|---|
| Title of host publication | Liver Cancer in the Middle East |
| Publisher | Springer International Publishing |
| Pages | 259-297 |
| Number of pages | 39 |
| ISBN (Electronic) | 9783030787370 |
| ISBN (Print) | 9783030787363 |
| DOIs | |
| Publication status | Published - Sept 22 2021 |
Keywords
- Cirrhosis
- DAA therapy
- Hepatitis C
- Hepatocellular carcinoma
- Middle East
ASJC Scopus subject areas
- General Medicine
